Latest insights from the TECOS Trial: clarifying the role for dipeptidyl peptidase-4 (DPP-4) inhibitors in the treatment of cardiovascular patients with type 2 diabetes and heart failure.
Topic:
Diabetes, dysglycaemia and metabolic syndrome
Speaker:
Doctor E. Peterson (Dallas, US)
Sponsored by MSD
Event:
ESC Congress 2017
Congress Presentation
About the speaker
Doctor Eric Peterson
UT Southwestern Medical Center, Dallas (United States of America)
15
presentations
0
follower
3 more presentations in this session
Opening remarks - A closer look at glucose lowering agents CV safety results and current heart failure guidelines.
Speaker: Doctor A. Gitt (Ludwigshafen, DE)
Roundtable discussion: what can we learn from current guidelines – Do they accurately reflect current knowledge and what can we expect over time?
Speaker: Doctor E. Peterson (Dallas, US) Professor L. Ryden (Stockholm, SE)
Closing remarks - A closer look at glucose lowering agents cardiovascular safety results and current heart failure guidelines.
Speaker: Doctor A. Gitt (Ludwigshafen, DE)
Access the full session
A closer look at glucose lowering agents cardiovascular safety results and current heart failure guidelines
Speakers:
Doctor E. Peterson, Doctor A. Gitt, Doctor E. Peterson, Professor L. Ryden, Doctor A. Gitt
About the event
